← Back to home

POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER

Clinical trials for POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER explained in plain language.

Never miss a new study

Get alerted when new POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER trials appear

Sign up with your email to follow new studies for POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Targeted drug tested to shrink tumors before lung cancer surgery

Disease control Ongoing

This study is testing whether a targeted drug called sunvozertinib can shrink tumors in people with a specific type of lung cancer before they have surgery. It is for adults with stage II-IIIB non-small cell lung cancer that has a particular genetic change called an EGFR exon 20 …

Matched conditions: POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER

Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control

Last updated Mar 02, 2026 15:23 UTC

POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER

Get alerted when new POTENTIALLY RESECTABLE EGFR EXON 20 INSERTION NON-SMALL CELL LUNG CANCER trials appear

Targeted drug tested to shrink tumors before lung cancer surgery